查找临床试验
已按「肺癌」检索，对应国际通用词 lung cancer
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 09:55，每 5 分钟自动同步Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
China
年龄 18 Years – 80 Years
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
China
年龄 18 Years – 不限
Shanghai Chest Hospital
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
China
年龄 18 Years – 75 Years
Second Xiangya Hospital of Central South University
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
China
年龄 18 Years – 75 Years
Jemincare
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
China
年龄 18 Years – 不限
Hoffmann-La Roche
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
China
年龄 18 Years – 75 Years
Zibo Municipal Hospital
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
China
年龄 18 Years – 不限
Peking University Cancer Hospital & Institute
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
United States、China、Israel、Japan、Puerto Rico 等 7 国
年龄 18 Years – 不限
AbbVie
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
China
年龄 18 Years – 75 Years
CSPC Megalith Biopharmaceutical Co.,Ltd.
Integrative Analysis of Large-cell Lung Cancer
China
年龄 18 Years – 75 Years
Shanghai 10th People's Hospital
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
China
年龄 18 Years – 75 Years
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
China
年龄 15 Years – 75 Years
Li-kun Chen